Corcept Therapeutics Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6
Corcept Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler
n/a
Temettü verimi
0.6%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 0.6% |
| Gelecekteki Temettü Verimi | 0% |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü ve geri alım güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • Sep 03
CORT: Cushing’s And Oncology Franchise Expansion Will Drive Future Upside
Analysts have lifted their fair value estimate for Corcept Therapeutics from $121 to $165, citing higher projected revenue growth, stronger profit margins, and a lower assumed future P/E multiple. This follows recent research that highlights Lifyorli's early oncology traction, ongoing Cushing's contributions, and updated longer term revenue guidance.Seeking Alpha • Aug 21
Like The Knick's, Corcept Rebounded And Is Crushing It
Summary Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli’s rapid launch for platinum-resistant ovarian cancer and Korlym’s resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low. Upcoming catalysts include an FDA decision on Relacorilant for Cushing syndrome, European approvals, and key trial results, with significant upside if milestones are met. CORT’s broad pipeline, cash-rich balance sheet, and aggressive salesforce expansion position it as a platform company addressing major disease categories. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 20
CORT: Ovarian Cancer Launch Will Shape Future Upside Outlook
Corcept Therapeutics' updated analyst price target has shifted from $88 to $141, reflecting analysts' focus on higher projected revenue growth, a revised future P/E near 21, and the potential impact of products like relacorilant and Lifyorli highlighted in recent research. Analyst Commentary Recent research on Corcept Therapeutics gives you a mix of strong optimism and pointed caution.
Anlatı Güncellemesi • Aug 06
CORT: Elevated Expectations Around Cushing’s Decision Will Shape Bearish Risk Outlook
Corcept Therapeutics' updated fair value estimate has moved from $88 to $50. This reflects analysts' wider range of views after several firms sharply raised their price targets into the $95 to $165 band, based on stronger recent results, expanded 2026 revenue guidance, and growing confidence in Lifyorli, Korlym, and the broader pipeline.Analiz Makalesi • Aug 05
We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings
Following the release of a lackluster earnings report from Corcept Therapeutics Incorporated ( NASDAQ:CORT ) the stock...Anlatı Güncellemesi • Jul 23
CORT: Regulatory Reset And New Indications Will Shape Balanced Risk Reward Outlook
For Corcept Therapeutics, the analyst-derived fair value estimate has been revised from $50 to $88, with analysts linking the higher target and increased assumed revenue growth to recent positive relacorilant regulatory updates and the potential for an additional indication. Analyst Commentary Recent research around Corcept Therapeutics highlights a mix of optimism around relacorilant and Lifyorli alongside pockets of caution, which matters if you are weighing how much execution or regulatory risk to price into the stock.Anlatı Güncellemesi • Jul 09
CORT: Regulatory Uncertainty Around Key NDA Resubmission Will Drive Future Downside Risk
Corcept Therapeutics' updated analyst price target of $50, down from $95, reflects analysts incorporating lower projected revenue growth, a slightly higher discount rate, and a more conservative future P/E multiple, even as they factor in improved profit margin assumptions and recent positive relacorilant and Lifyorli milestones. Analyst Commentary Recent Street research on Corcept Therapeutics has centered on the regulatory path for relacorilant, the commercial outlook for Lifyorli in ovarian cancer, and how these factors feed into valuation assumptions.Anlatı Güncellemesi • Jun 25
CORT: Ovarian Cancer Launch And Cushing’s Review Will Shape Balanced Outlook
Analysts have lifted their price targets on Corcept Therapeutics to a range of $72 to $135, citing the positive relacorilant NDA resubmission, the recent Lifyorli approval, and greater clarity on the regulatory path as key reasons for the higher valuation views. Analyst Commentary Recent research on Corcept Therapeutics points to a more constructive view on the stock, with several firms lifting price targets after the relacorilant NDA resubmission and the approval of Lifyorli.Anlatı Güncellemesi • Jun 06
CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside
Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.Anlatı Güncellemesi • May 11
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.Anlatı Güncellemesi • Apr 25
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.Anlatı Güncellemesi • Apr 11
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.Anlatı Güncellemesi • Mar 27
CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.Anlatı Güncellemesi • Mar 10
CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.Anlatı Güncellemesi • Feb 24
CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.Anlatı Güncellemesi • Feb 09
CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.Anlatı Güncellemesi • Jan 26
CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.Anlatı Güncellemesi • Jan 10
CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.Analiz Makalesi • Jan 01
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...Anlatı Güncellemesi • Dec 17
CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.Analiz Makalesi • Oct 07
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: CORT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: CORT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi
| Corcept Therapeutics Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (CORT) | n/a |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.1% |
| Sektör Ortalaması (Pharmaceuticals) | 1.9% |
| Analist tahmini (CORT) (3 yıla kadar) | 0% |
Önemli Temettü: CORT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CORT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: CORT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: CORT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/11 13:57 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Corcept Therapeutics Incorporated 19 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |